Jaguar Health (JAGX) Share-based Compensation (2014 - 2026)
Jaguar Health's (JAGX) quarterly Share-based Compensation came in at $452.0 million in Q1 2026, up 132451.32% year-on-year from N/an in Q1 2025, and up 92144.9% on a QoQ basis from $490000.0 in Q4 2025.
Jaguar Health (JAGX) Share-based Compensation (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 13 years of Share-based Compensation data on file, last reported at $452.0 million in Q1 2026.
- On a quarterly basis, Share-based Compensation rose 132451.32% year-over-year to $452.0 million in Q1 2026; TTM through Mar 2026 was $452.0 million, a 18303.91% increase from a year earlier, with the FY2025 full-year figure at $569.0 million, down 99.92% from the prior year.
- Share-based Compensation for Q1 2026 stood at $452.0 million, up from $490000.0 in the prior quarter.
- Over the last five years, Share-based Compensation for JAGX reached as high as $452.0 million in Q1 2026 and fell as low as $90000.0 in Q1 2022.
- Historically, Share-based Compensation has averaged $52.3 million across 5 years, with a median of $490000.0 in 2025.
- Across the five-year window, Share-based Compensation tumbled 87.57% in 2022 and surged 138287.1% in 2025, its largest moves.
- Year by year, Share-based Compensation stood at $142000.0 in 2022, then soared by 306.34% to $577000.0 in 2023, then jumped by 146.45% to $1.4 million in 2024, then slumped by 65.54% to $490000.0 in 2025, then jumped by 92144.9% to $452.0 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $452.0 million in Q1 2026, $490000.0 in Q4 2025, and $429.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,782.24 Bn | 1,782.18 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 305,000.00 |
| 3 | BeOne Medicines | 473.46 Bn | 468.66 Bn | 1.35 Bn | 9.26 Mn |
| 4 | Vertex Pharmaceuticals | 123.84 Bn | 116.59 Bn | 2.59 Bn | 166.40 Mn |
| 5 | Regeneron Pharmaceuticals | 71.69 Bn | 62.94 Bn | 3.31 Bn | 257.40 Mn |
| 6 | Belite Bio | 62.15 Bn | 62.15 Bn | - | - |
| 7 | Argenx Se | 54.74 Bn | 49.55 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.08 Bn | 35.07 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.07 Bn | 36.07 Bn | - | 87.30 Mn |
| 10 | Jaguar Health | 520,945.88 | -9.54 Mn | 19.11 Mn | 452.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 452.00 Mn |
| Mar 31, 2026 | 452.00 Mn |
| Dec 31, 2025 | 490,000.00 |
| Dec 31, 2025 | 490,000.00 |
| Sep 30, 2025 | 429.00 Mn |
| Sep 30, 2025 | 429.00 Mn |
| Jun 30, 2025 | 279,000.00 |
| Jun 30, 2025 | 279,000.00 |
| Mar 31, 2025 | 341,000.00 |
| Mar 31, 2025 | 341,000.00 |
| Dec 31, 2024 | 1.42 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Sep 30, 2024 | 310,000.00 |
| Sep 30, 2024 | 310,000.00 |
| Jun 30, 2024 | 383,000.00 |
| Jun 30, 2024 | 383,000.00 |
| Mar 31, 2024 | 221,000.00 |
| Mar 31, 2024 | 221,000.00 |
| Dec 31, 2023 | 577,000.00 |
| Dec 31, 2023 | 577,000.00 |